Supplementary Figures 1 - 2 from Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 156K, Supplementary Fig. S1. Concentration-time plots of the first 72 hours after administration of the first vismodegib dose during Course 1 to the patients in the initial cohort: 6 received 85 mg/m2 (Figure A & B), and 7 received 170 mg/m2 (Figure C &D). Plasma concentrations of total vismodegib (A, C) and unbound vismodegib (B, D) were measured. Supplementary Fig S2. The relation between total vismodegib plasma concentrations and alpha-1-acid glycoprotein (AAGP) plasma concentrations in pediatric patients. The scatter plot includes all data from patients treated in this study. The solid line represents the best-fit line from linear regression analysis (R2= 0.38).
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361883236